Status:
RECRUITING
Antibody-mediated LGI1 Encephalitis: Symptoms, Biomarkers, and Mechanisms of the Chronic Phase of the Disease
Lead Sponsor:
Fundacion Clinic per a la Recerca Biomédica
Conditions:
Limbic Encephalitis With LGI1 Antibodies
Eligibility:
All Genders
Phase:
NA
Brief Summary
The encephalitis mediated by antibodies against Leucine-rich, glioma inactivated 1 protein (anti-LGI1 encephalitis) predominantly affects men (M:F, 6:4) and mostly older than 60 years. The disease has...
Eligibility Criteria
Inclusion
- Patients with Antibody-mediated LGI-1 encephalitis in the post-acute stage of the disease;
- Patients has been discharged from hospital (acute phase).
Exclusion
- Inability to obtain informed consent;
- Inability to travel to the center.
Key Trial Info
Start Date :
December 18 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2026
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT06515106
Start Date
December 18 2023
End Date
December 31 2026
Last Update
July 23 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hospital Clínic de Barcelona
Barcelona, Catalonia, Spain, 08036